Inclusion Criteria:  Patients who have started at first time on Esgliteo in accordance with the approved label in Korea Age ≥19 years at enrolment Patients who have signed on the data release consent form  Exclusion Criteria:  Patients with previous exposure to Esgliteo Patients with hypersensitivity to the empagliflozin and/or linagliptin or any of the excipients Patients with type 1 diabetes or diabetic ketoacidosis Patients with estimated Glomerular Filtration Rate (eGFR) < 45 mL/min/1.73m2, end stage renal disease, or patient on dialysis Patients for whom empagliflozin/linagliptin is contraindicated according to the local label of Esgliteo